Drug intelligence / Profile preview

WD-1804

Development stage: Preclinical
Lead developer: Shanghai WD Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**WD-1804** is an investigational oral, controlled-release **carbidopa + levodopa** drug-device combination from **WD Pharmaceutical** for advanced Parkinson's disease. The product uses the company's UGiPump upper-gastrointestinal retention and drug-delivery technology to prolong upper-GI levodopa absorption and provide a sustained, relatively steady levodopa plasma-concentration profile, intended as a non-invasive alternative to intestinal levodopa infusion approaches such as Duopa. WD Pharmaceutical describes the program as having completed pre-IND meetings with the FDA and planned for an IND submission for Phase I/II development. ([en.wdpharma.com](https://en.wdpharma.com/show-130.html))

Other names: Carbidopa-Levodopa Oral Controlled-Release Tablets

Targets

DDC (Aromatic L-amino acid decarboxylase)

Beyond the preview

Go deeper on WD-1804.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-1804.

Explore the full profile